← back to search

Markus Schwaiger

UMIT - Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik · AT
Area of research
Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Medical Imaging Techniques and Applications, Cardiac Imaging and Diagnostics, Radiopharmaceutical Chemistry and Applications, and Advanced MRI Techniques and Applications.
h-index
151
citations
84,412
works
1,690
NIH funding
primary concept
email

Recent publications

Adjustment for the Age- and Gender-Related Metabolic Changes Improves the Differential Diagnosis of Parkinsonism.
2023cited by 14position: contributordoi
Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning
European Journal of Nuclear Medicine and Molecular Imaging 2022cited by 50position: middledoi
Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using <sup>68</sup>Ga-FAPI-04.
2022cited by 45position: contributordoi
Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy
EJNMMI Research 2022cited by 14position: middledoi
PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK)
European Journal of Cancer 2022cited by 11position: middledoi
Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC
Scientific Reports 2021cited by 24position: middledoi
Diverse metabolic response of cancer cells treated with a 213Bi-anti-EGFR-immunoconjugate
Scientific Reports 2021cited by 8position: middledoi
Author Correction: Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC
Scientific Reports 2021cited by 2position: middledoi
Radiotheranostics: a roadmap for future development
The Lancet Oncology 2020cited by 288position: middledoi
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
The Lancet Oncology 2020cited by 173position: middledoi
CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma
Journal of Nuclear Medicine 2020cited by 50position: middledoi
Dynamic 2D and 3D mapping of hyperpolarized pyruvate to lactate conversion in vivo with efficient multi‐echo balanced steady‐state free precession at 3 T
NMR in Biomedicine 2020cited by 21position: middledoi
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation
PLoS ONE 2019cited by 11position: middledoi
Assessment of 213Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-13C]pyruvate and [18F]FDG
Scientific Reports 2019cited by 8position: middledoi
PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial.
Journal of Clinical Oncology 2019cited by 7position: middledoi
Detection Efficacy of <sup>18</sup>F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
Journal of Nuclear Medicine 2018cited by 330position: middledoi
Efficacy, Predictive Factors, and Prediction Nomograms for 68 Ga-labeled Prostate-specific Membrane Antigen–ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy
European Urology 2018cited by 169position: middledoi
One-Stop-Shop Whole-Body <sup>68</sup>Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer
Journal of Nuclear Medicine 2018cited by 68position: middledoi
Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized <sup>13</sup>C-MRSI
Theranostics 2018cited by 43position: lastdoi
T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target
Theranostics 2018cited by 37position: middledoi
Hyperpolarized Amino Acid Derivatives as Multivalent Magnetic Resonance pH Sensor Molecules
Sensors 2018cited by 35position: middledoi
A Novel Approach for Image-Guided 131I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery
Molecular Cancer Research 2018cited by 33position: middledoi
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors
The Journal of Experimental Medicine 2017cited by 193position: middledoi
Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
European Journal of Nuclear Medicine and Molecular Imaging 2017cited by 140position: middledoi
Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
Theranostics 2017cited by 105position: middledoi
Detection Efficacy of Hybrid <sup>68</sup>Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria
Journal of Nuclear Medicine 2017cited by 80position: middledoi
Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene
Oncotarget 2017cited by 38position: middledoi
In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET
Theranostics 2017cited by 33position: middledoi
<sup>68</sup>Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer
Journal of Nuclear Medicine 2017cited by 30position: middledoi
Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities
EJNMMI Research 2017cited by 28position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Katja Steiger · Technical University of Munich10 papers (2016–2021)Matthias Eiber · Comprehensive Cancer Center Erlangen10 papers (2015–2018)Ulrich Keller · SLK-Kliniken Heilbronn9 papers (2014–2020)Isabel Rauscher · München Klinik9 papers (2014–2022)Tobias Maurer · Eppendorf (Germany)8 papers (2015–2018)Jens T. Siveke · Heinrich Heine University Düsseldorf7 papers (2016–2022)Julia Slotta‐Huspenina · Starnberg Hospital7 papers (2015–2022)Wolfgang Weber · Tumkur University7 papers (2018–2022)Peter Herhaus · TUM Klinikum6 papers (2015–2020)Stefan Habringer · University of Applied Sciences Upper Austria6 papers (2015–2020)Franz Schilling · German Cancer Research Center6 papers (2017–2021)Bernhard Haller · Technical University of Munich6 papers (2015–2022)Christian Hundshammer · Technical University of Munich6 papers (2018–2021)Hans‐Jürgen Wester · Theranostics (New Zealand)6 papers (2015–2020)Tibor Vág · Technical University of Munich5 papers (2015–2020)Marija Trajkovic‐Arsic · German Cancer Research Center5 papers (2016–2021)Christian Peschel · Klinikum rechts der Isar5 papers (2015–2017)Benedikt Feuerecker · Novartis (Switzerland)5 papers (2017–2021)Rickmer Braren · Universität Hamburg4 papers (2016–2021)Wilko Weichert · German Cancer Research Center4 papers (2018–2022)